Ebola Vaccine Booster Produced Positive Immune Response

INOVIO today announced that Dr. Angela Huttner, Infectious Disease Consultant, Geneva University Hospitals presented data from a Phase 1b trial evaluating INO-4201, an Ebola booster vaccine candidate for rVSV-ZEBOV (Ervebo®).

"Preliminary data showed that INO-4201 was well tolerated and produced a strong immune response," stated Dr. Huttner in a press release on April 17, 2023.

"This suggests that a booster dose of IN0-4201 has the potential to extend protection against Ebola and could be an important tool in future Ebola Virus Disease prevention."

In February 2023, INOVIO announced positive initial results from the Phase 1b trial that evaluated INO-4201 as a booster in healthy adult participants who previously received a single injection of Ervebo.

These initial results showed that INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants. In addition, data presented today included the assessment of binding antibodies showing that all 36 vaccine recipients responded to the boost.

The unedited press release is posted at this link.

Note: Merck's Ervebo® Vaccine is a live, recombinant, replication-competent vaccine approved by the U.S. FDA and by the European Medicines Agency.

Since 2019, approximately 300,000 persons have been vaccinated with the Ervebo vaccine in Africa.

Other Ebolavirus (Zaire and Sudan) vaccine and outbreak(s) news is posted at Vax-Before-Travel.